Replies to post #246662 on Biotech Values

[dewophile]

Thanks
I think asking about the SGEN data that is already public should be fair game, but certainly not from ongoing trials. it is a large purchase after all, and I would have wanted to know why they dropped their PD-1 given data that the combination with ADCs seems promising. I just find that odd unless they have tons of faith in their SQ PD-1
Given the stock performance buybacks make more sense than dividends
I'll wait for the transcript curious about GLP-1 program and vaccines more so than oncology